Laboratorios Farmaceuticos ROVI (ROVI)
Madrid Exchange · Spain · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 59.45 |
|---|---|
| 52-week range | 53.10 – 86.70 |
| Return, 1 month / 3 months | +0.6% / +5.8% |
| Return, 1 year / 3 years | −6.0% / +26.0% |
| Trend | Below its 200-day average |
| RSI (14) | 55 |
| Volatility (1 year) | 28.1% |
| Worst drawdown (1 year) | -36.2% |
| Average daily value traded | 5.34M EUR |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Laboratorios Farmaceuticos ROVI is a Spanish pharmaceutical company based in Madrid. It develops and manufactures medicines, with a focus on injectable anticoagulants such as enoxaparin, along with contrast agents and other hospital products. ROVI supplies hospitals and healthcare providers, and it also makes drugs for other pharmaceutical companies under contract manufacturing arrangements. Its business spans research, development, production and marketing of its own and partner medicines, largely for markets in Europe and beyond.
On this site Laboratorios Farmaceuticos ROVI appears as a stock on the Madrid Exchange (Spain), code ROVI, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Laboratorios Farmaceuticos ROVI (ROVI) trades on the Madrid Exchange in Spain. It last closed at EUR 59.45 on 22 October 2026.
Its price-based Market X-Ray is 40 out of 100 (a weak price profile), ranking 167 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 6.0% and over the last three months it rose 5.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 22 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -9.4% | ||
| From 52-week high | -30.5% | ||
| Momentum | 44 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 5.8% | ||
| 6-month return | -29.1% | ||
| 12-month return, skipping the last month | -6.6% | ||
| Stability (higher is calmer) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 28.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.2% | ||
| Liquidity | 87 · Strong | Trades actively. | |
| Average daily value traded | 5.34M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 34 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.2% |
|---|---|
| 1 month | +0.6% |
| 3 months | +5.8% |
| 6 months | −29.1% |
| 1 year | −6.0% |
| 3 years | +26.0% |
| 5 years | +9.0% |
Signals
| 50-day / 200-day average | 58.80 / 65.61 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.27 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Jul 2026 | EUR 0.9594 |
| 14 Jul 2025 | EUR 0.9351 |
| 8 Jul 2024 | EUR 1.1037 |
| 3 Jul 2023 | EUR 1.2938 |
| 5 Jul 2022 | EUR 0.9556 |
| 5 Jul 2021 | EUR 0.3812 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.